TY - JOUR
T1 - The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma
T2 - A judicious option?
AU - Delaunoit, Th
AU - Ducreux, M.
AU - Boige, V.
AU - Dromain, C.
AU - Sabourin, J. C.
AU - Duvillard, P.
AU - Schlumberger, M.
AU - De Baere, T.
AU - Rougier, P.
AU - Ruffie, P.
AU - Elias, D.
AU - Lasser, P.
AU - Baudin, E.
PY - 2004/1/1
Y1 - 2004/1/1
N2 - Due to their rarity, only few trials have studied the role of the doxorubicin-streptozotocin (DS) combination in advanced well-differentiated pancreatic endocrine carcinomas (AWDPEC). However, the published results are inconsistent. We reviewed all AWDPEC (5-year period, 45 patients) treated in our institution with the DS combination for: objective response rate (ORR), progression-free survival, overall survival (OS) and toxicity. An ORR of 36% (95% Confidence Interval (CI) 22-49) was obtained, with 16 partial responses (PR). The mean duration of PR was of 19.7 months. Two and 3-year OS rates were 50.2 and 24.4%, respectively. Toxicities were mainly digestive (grade ≥3 vomiting, 13%) and haematological (grade ≥3 neutropenia, 24%). Previous systemic chemotherapy and malignant hepatomegaly were associated with a poorer ORR (P=0.033, P=0.016) and OS (P=0.008, P=0.045). Multivariate analysis demonstrated previous chemotherapy as the only independent predictive-factor for survival (P=0.013). In conclusion, our data confirm the sensitivity of AWDPEC to the DS combination, with an ORR of 36% and a remarkable median response duration of 19.7 months, and suggests that it could be considered as a valid option in first-line therapy.
AB - Due to their rarity, only few trials have studied the role of the doxorubicin-streptozotocin (DS) combination in advanced well-differentiated pancreatic endocrine carcinomas (AWDPEC). However, the published results are inconsistent. We reviewed all AWDPEC (5-year period, 45 patients) treated in our institution with the DS combination for: objective response rate (ORR), progression-free survival, overall survival (OS) and toxicity. An ORR of 36% (95% Confidence Interval (CI) 22-49) was obtained, with 16 partial responses (PR). The mean duration of PR was of 19.7 months. Two and 3-year OS rates were 50.2 and 24.4%, respectively. Toxicities were mainly digestive (grade ≥3 vomiting, 13%) and haematological (grade ≥3 neutropenia, 24%). Previous systemic chemotherapy and malignant hepatomegaly were associated with a poorer ORR (P=0.033, P=0.016) and OS (P=0.008, P=0.045). Multivariate analysis demonstrated previous chemotherapy as the only independent predictive-factor for survival (P=0.013). In conclusion, our data confirm the sensitivity of AWDPEC to the DS combination, with an ORR of 36% and a remarkable median response duration of 19.7 months, and suggests that it could be considered as a valid option in first-line therapy.
KW - Chemotherapy
KW - Neuroendocrine carcinoma
KW - Pancreas
UR - http://www.scopus.com/inward/record.url?scp=10744226279&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2003.09.035
DO - 10.1016/j.ejca.2003.09.035
M3 - Article
C2 - 14962717
AN - SCOPUS:10744226279
SN - 0959-8049
VL - 40
SP - 515
EP - 520
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 4
ER -